3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors

US11352334B2 · kind B2 · utility

Assignee

• The University Court of the University of Edinburgh · GB

Inventors

• Anne Marie Jeanne Bouillot · Les Ulis, FR
• Olivier Mirguet · Les Ulis, FR
• John Liddle · Stevenage, GB
• Anne Louise WALKER · Stevenage, GB

Key dates

• Filing date: Jul 24, 2019
• Grant date: Jun 7, 2022
• Expiry date: Jul 24, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.